Abstract: Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Type:
Grant
Filed:
July 24, 2015
Date of Patent:
February 6, 2018
Assignee:
INNOV17 LLC
Inventors:
Anderson Gaweco, Jefferson Tilley, James Blinn
Abstract: Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Type:
Grant
Filed:
July 24, 2015
Date of Patent:
September 26, 2017
Assignee:
INNOV17 LLC
Inventors:
Anderson Gaweco, Jefferson Tilley, James Blinn
Abstract: Provided herein are compounds of the formulas (I) and (II), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Type:
Application
Filed:
July 24, 2015
Publication date:
August 3, 2017
Applicant:
INNOV17 LLC
Inventors:
Anderson Gaweco, Jefferson Tilley, James Blinn
Abstract: The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.
Type:
Grant
Filed:
April 30, 2013
Date of Patent:
July 18, 2017
Assignee:
INNOV17 LLC
Inventors:
Anderson Gaweco, Jefferson W. Tilley, John Walker, Samantha Palmer, James Blinn
Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
Type:
Grant
Filed:
July 24, 2015
Date of Patent:
July 11, 2017
Assignee:
INNOV17 LLC
Inventors:
Anderson Gaweco, Jefferson Tilley, James Blinn
Abstract: The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.
Type:
Grant
Filed:
April 30, 2013
Date of Patent:
September 20, 2016
Assignee:
INNOV17 LLC
Inventors:
Anderson Gaweco, Jefferson W. Tilley, John Walker, Samantha Palmer, James Blinn
Abstract: The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR. The invention is based in part on the discovery of ROR modulators which interact with RORa and/or RORy and thereby inhibit or induce RORa and/or RORy-activity, and RORa- and/or RORy-regulated target gene and protein expression.
Type:
Grant
Filed:
April 22, 2013
Date of Patent:
April 26, 2016
Assignee:
INNOV17 LLC
Inventors:
Anderson Gaweco, Jefferson W. Tilley, John Walker, Samantha Palmer, James Blinn